Related Experiment Videos
Propranolol absorption in peptic ulcer disease
A Valdivieso1, R Calvo, E Suarez
1Dept. of Surgery, Galdakano Hospital, Vizcaya, Spain.
Scandinavian Journal of Gastroenterology
|July 1, 1993
Summary
Gastroduodenal ulcers slow propranolol absorption in patients. However, this effect on propranolol pharmacokinetics does not appear to have a significant clinical impact after a single dose.
Area of Science:
- Pharmacology
- Gastroenterology
- Clinical Medicine
Background:
- Peptic ulcer disease is a common gastrointestinal condition.
- Propranolol is a beta-blocker used to treat various cardiovascular conditions.
Purpose of the Study:
- To investigate the impact of gastroduodenal ulcers on the oral absorption of propranolol.
- To compare propranolol pharmacokinetics in patients with peptic ulcer disease versus healthy subjects.
Main Methods:
- Oral administration of 80 mg propranolol to 11 ulcer patients and 8 healthy controls.
- Quantification of serum propranolol levels using high-performance liquid chromatography (HPLC).
- Analysis of pharmacokinetic parameters including peak concentration, absorption constant, and area under the concentration-time curve (AUC).
Main Results:
- Ulcer patients exhibited significantly lower mean peak propranolol concentrations (90 vs. 151 ng/ml).
- A reduced absorption constant (0.96 vs. 1.43 h-1) and AUC (492 vs. 802 ng/ml.h) were observed in ulcer patients.
- No significant difference in the cardiac effects of propranolol was noted at 90 minutes post-administration.
Conclusions:
- Gastroduodenal ulcer disease is associated with delayed and reduced oral absorption of propranolol.
- Despite altered pharmacokinetics, a single dose of propranolol does not produce clinically significant differences in cardiac effects between ulcer patients and healthy individuals.